Print selected from 10551870.trn

>
Uploading C:\Program Files\Stnexp\Queries\10551870_basic.str



chain nodes :
7
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18 19
chain bonds :
2-7 7-8 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19
15-16 16-17 17-18 18-19
exact/norm bonds :
2-7 7-8 14-15 14-19 15-16 16-17 17-18 18-19
exact bonds :
13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 16:26:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 444 TO ITERATE

100.0% PROCESSED 444 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7616 TO 10144
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> s l1 full

```
Print selected from 10551870.trn

FULL SEARCH INITIATED 16:26:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     8851 TO ITERATE

100.0% PROCESSED     8851 ITERATIONS                                103 ANSWERS
SEARCH TIME: 00.00.01

L3          103 SEA SSS FUL L1

=> FIL STNGUIDE
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     172.10     172.31

FILE 'STNGUIDE' ENTERED AT 16:26:41 ON 05 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb  2, 2007 (20070202/UP).

=> file caplus/caold
'CAPLUS/CAOLD' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'STNGUIDE'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file caplus caold
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.18     172.49

FILE 'CAPLUS' ENTERED AT 16:28:15 ON 05 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAOLD' ENTERED AT 16:28:15 ON 05 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l3
L4          12 L3

=> D BIB ABS HITSTR 1-12

L4   ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:1252802  CAPLUS <<LOGINID::20070205>>
DN   146:27814
TI   Pyrrolopyridines useful as inhibitors of protein kinase and their
     preparation, pharmaceutical compositions, and use in the treatment of
     various diseases
IN   Ledeboer, Mark W.; Wannamaker, Marion W.; Farmer, Luc J.; Wang, Tiansheng;
     Pierce, Albert C.; Martinez-Botella, Gabriel; Bethiel, Randy S.; Bemis,
     Guy W.; Wang, Jian; Salituro, Francesco G.; Arnost, Michael J.; Come, Jon
     H.; Green, Jeremy; Stewart, Michelle; Marhefka, Craig
PA   Vertex Pharmaceuticals Incorporated, USA
SO   PCT Int. Appl., 201pp.
     CODEN: PIXXD2
```

Print selected from 10551870.trn

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006127587	A1	20061130	WO 2006-US19711	20060522

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-683554P P 20050520
OS MARPAT 146:27814
GI



AB The invention relates to compds. of formula I, which are useful as inhibitors of protein kinases, particularly of JAK family and ROCK family kinases. The invention also provides pharmaceutically acceptable compns. comprising said compds. and methods of using the compns. in the treatment of various disease, conditions, or disorders. Compds. of formula I wherein Q is a (un)substituted (un)saturated 3- to 8-membered (hetero)monocyclic ring and (un)saturated 8- to 12-membered (hetero)bicyclic ring; Z is a bond, NH, C1-3 alkylamine, and C=CH2; R1 and R2 are independently (un)substituted C1-2 alkyl; R3 is H, Cn, NO2, (un)substituted C1-6 aliphatic; and their pharmaceutically acceptable salts thereof are claimed. Example compound II was prepared by cross-coupling of 4-bromo-1-tosyl-1H-[2,3-b]pyridine with 3-dimethylaminophenylboronic acid derivative All the invention compds. were evaluated for their JAK and ROCK kinase inhibitory activity. From the kinase inhibition assay, it was determined that compound II exhibited Ki values of less than 0.5 μM against JAK2, JAK3 and ROCK-I.

IT **916174-40-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrrolopyridines as inhibitors of protein kinase useful in the treatment of various diseases)

RN 916174-40-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-(2-phenoxyphenyl)- (CA INDEX NAME)

Print selected from 10551870.trn



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:11154 CAPLUS <<LOGINID::20070205>>
DN 144:108105
TI Phenoxynaphthalene derivatives as selective estrogen receptor modulators, their preparation, pharmaceutical compositions, and use in therapy
IN Heyer, Dennis; Fang, Jing; Navas, Frank, III; Katamreddy, Subba Reddy; Peckham, Jennifer Poole; Turnbull, Philip Stewart; Miller, Aaron Bayne; Akwabi-Ameyaw, Adwoa
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006002185	A1	20060105	WO 2005-US21963	20050621
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-581913P	P	20040622		

OS MARPAT 144:108105
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to phenoxynaphthalene compds. of formula I, which are useful for selective estrogen receptor modulation. In compds. I, R1 is H, OH, halo, or (un)substituted alkoxy; R2 is H, OH, or halo; R3 is (un)substituted alkyl, haloalkyl, (un)substituted cycloalkyl, (un)substituted alkoxy, or (un)substituted alkoxyalkyl; R4 is H or (un)substituted alkoxy; R5 is H, halo, or haloalkyl; R6 is R7-Y-, where Y is a bond, (un)substituted ethenyl, or ethynyl and R7 is (un)substituted alkyl, (un)substituted alkoxy, (un)substituted aryl, (un)substituted

heteroaryl, (un)substituted heterocyclyl, cyano, carboxy, etc.; and R8 is (un)substituted aryl or (un)substituted heteroaryl. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment or prevention of conditions or disorders affected by selective estrogen receptor modulation. Hydride reduction of ketone II followed by mesylation, bromination, and substitution with phenylacetic acid gave carboxylic acid III, which underwent cyclization to the corresponding dihydronaphthalenone, oxidative acetylation, and hydrolysis to give naphthol IV. 3,4-Difluorobenzaldehyde was substituted with IV followed by Wittig olefination with tri-Et phosphonoacetate, ester hydrolysis, and demethylation, resulting in the formation of (E)-propenoic acid V. The tested compds. of the invention exhibited pIC50 values ranging from 1 nM to 10 μM in an estrogen receptor competition binding assay.

IT **872550-85-1P**, 3-[4-(6-Methoxy-3-methyl-2-(pyridin-4-yl)naphthalen-1-yloxy)phenyl]acrylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenoxynaphthalenes as selective estrogen receptor modulators)

RN 872550-85-1 CAPLUS

CN 2-Propenoic acid, 3-[4-[[6-methoxy-3-methyl-2-(4-pyridinyl)-1-naphthalenyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



IT **872550-83-9P**, 4-(6-Methoxy-3-methyl-2-(pyridin-4-yl)naphthalen-1-yloxy)benzaldehyde
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of phenoxynaphthalenes as selective estrogen receptor modulators)

RN 872550-83-9 CAPLUS

CN Benzaldehyde, 4-[[6-methoxy-3-methyl-2-(4-pyridinyl)-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:371204 CAPLUS <<LOGINID::20070205>>
DN 142:430015
TI Preparation of phenoxyether derivatives as PPAR modulators
IN Winneroski, Leonard Larry, Jr.; Xu, Yanping; York, Jeremy Schulenburg
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005037763	A1	20050428	WO 2004-US30911	20041008
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2541751	A1	20050428	CA 2004-2541751	20041008
	EP 1675814	A1	20060705	EP 2004-793892	20041008
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	US 2003-510865P	P	20031014		
	WO 2004-US30911	W	20041008		

OS MARPAT 142:430015
GI



I

Print selected from 10551870.trn

AB Title compds. I [E1-5 = CH, CR5, or at least one of E1-5 = N and others are CH, CR5; A = bond, CH2, etc.; Q = carboxy; p = 1-4; R1-2 = H, alkyl, etc.; R3-4 = H, NO2, CN, OH, etc.; R5 = H, NO2, CN, etc.] are prepared For instance, [[4-[3-(4-chloro-2-phenoxyphenoxy)phenoxy]-2-methylphenyl]sulfanyl]acetic acid is prepared in 2 steps from 4-chloro-2-phenoxyphenol, 1-bromo-3-iodobenzene and [(4-hydroxy-2-methylphenyl)sulfanyl]acetic acid Et ester. Example compds. bind to peroxisome proliferator activated receptor-α (PPARα), PPARγ and PPARδ in the range of 1 - 1000 nM. I are useful in treating or preventing syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

IT **850793-10-1P**, 3-[2-Methyl-4-[3-methyl-5-[2-pyridin-4-yl-4-(trifluoromethyl)phenoxy]phenoxy]phenyl]propionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenoxyether derivs. as PPAR modulators)

RN 850793-10-1 CAPLUS

CN Benzenepropanoic acid, 2-methyl-4-[3-methyl-5-[2-(4-pyridinyl)-4-(trifluoromethyl)phenoxy]phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:857400 CAPLUS <<LOGINID::20070205>>
DN 141:332061
TI Preparation of [(phenoxy)phenyl]piperidine derivatives as serotonin reuptake inhibitors
IN Bang-andersen, Benny; Kroll, Friedrich; Kehler, Jan
PA H. Lundbeck A/S, Den.
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004087155	A1	20041014	WO 2004-DK241	20040402

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

Print selected from 10551870.trn

	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,				
	SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,				
	TD, TG				
AU	2004226837	A1	20041014	AU 2004-226837	20040402
CA	2521030	A1	20041014	CA 2004-2521030	20040402
BR	2004008320	A	20060307	BR 2004-8320	20040402
EP	1635828	A1	20060322	EP 2004-725298	20040402
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN	1767829	A	20060503	CN 2004-80008884	20040402
JP	2006522027	T	20060928	JP 2006-504346	20040402
NO	2005005206	A	20051104	NO 2005-5206	20051104
US	2006293360	A1	20061228	US 2005-551870	20051116
PRAI DK	2003-519	A	20030404		
US	2003-460265P	P	20030404		
WO	2004-DK241	W	20040402		

OS MARPAT 141:332061

GI



I

AB Title compds. represented by the formula I [wherein R1-R5 = independently H, halo, cyano, alkenyl, etc.; R6-R9 = independently H, halo, alkynyloxy, etc.; and pharmaceutically acceptable salts thereof] were prepared as serotonin reuptake inhibitors. For example, I (R1 = R3 = Me, R2, R4-R9 = H) was given in a multi-step synthesis starting from the reaction of 2,4-dimethylphenol with 1-bromo-2-fluorobenzene. I showed inhibition of the norepinephrine and serotonine reuptake with IC50 below 200 nM. Thus, I and their pharmaceutical compns. are useful as serotonin reuptake inhibitors in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder (no data).

IT **773853-11-5P 773853-12-6P 773853-14-8P**
773853-16-0P 773853-18-2P 773853-20-6P
773853-22-8P 773853-24-0P, 4-[2-(4-Chlorophenoxy)phenyl]piperidine **773853-25-1P**
773853-27-3P, 4-[2-(4-Fluorophenoxy)phenyl]piperidine
773853-28-4P 773853-30-8P 773853-31-9P
773853-32-0P 773853-33-1P 773853-34-2P
773853-35-3P 773853-36-4P 773853-37-5P

Print selected from 10551870.trn

773853-38-6P 773853-39-7P 773853-40-0P
773853-41-1P 773853-42-2P 773853-43-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(phenoxy)phenyl]piperidine derivs. as serotonin reuptake inhibitors)

RN 773853-11-5 CAPLUS
CN Pyridine, 4-[2-(2,4-dimethylphenoxy)phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 773853-12-6 CAPLUS
CN Pyridine, 4-[2-(4-chlorophenoxy)phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn

4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:695975 CAPLUS <<LOGINID::20070205>>
DN 137:232913
TI Preparation of peptides for pharmaceutical use as modulators of melanocortin receptors
IN Yu, Guixue; Macor, John; Herpin, Timothy; Lawrence, R. Michael; Morton, George C.; Ruel, Rejean; Poindexter, Graham S.; Ruediger, Edward H.; Thibault, Carl
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070511	A1	20020912	WO 2002-US6479	20020302
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2437594	A1	20020912	CA 2002-2437594	20020302
	EP 1363898	A1	20031126	EP 2002-723310	20020302
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 200401544	A2	20041228	HU 2004-1544	20020302
	JP 2005511475	T	20050428	JP 2002-569831	20020302
	US 2003092732	A1	20030515	US 2002-90582	20020304
	US 6979691	B2	20051227		
	US 2003096827	A1	20030522	US 2002-90288	20020304
	US 6713487	B2	20040330		
	US 2004229882	A1	20041118	US 2003-696761	20031029
	US 7067525	B2	20060627		
	US 2006025403	A1	20060202	US 2005-199464	20050808
PRAI	US 2001-273206P	P	20010302		
	US 2001-273291P	P	20010302		
	WO 2002-US6479	W	20020302		
	US 2002-90288	A3	20020304		
	US 2002-90582	A3	20020304		

OS MARPAT 137:232913
GI



I

AB Compds. W-(CR6R7)yCH(G)(CR4R5)xCO-X(R1)CHR2(CHR3)r(CH2)sCO-E [X = N or CH; R1, R3 = H or alkyl; R2 = H, aryl, cycloalkyl, heteroaryl, heterocyclyl, (un)substituted alkyl or alkenyl; R1 together with R2 or R3 or R2 together with R3 form mono- or bicyclic aryl, cycloalkyl, heteroaryl, or

Print selected from 10551870.trn

heterocyclyl; E = (un)substituted pyrrolidino, piperidino, hexahydro-1-azepinyl, 1-piperazinyl, cyclopentyl, cyclohexyl, cycloheptyl, amino, (cyclo)alkylamino; R4-R6 = H, (un)substituted alkyl, amino, alkylamino, hydroxy, alkoxy, aryl, cycloalkyl, heteroaryl, or heterocyclyl; or CR4R5 or C6R7 is a spirocycloalkyl ring; r, s = 0 or 1; x = 0-4; y = 0-2; G = alkenyl, arylalkenyl, hydroxy, heteroaryl, cyano, functionalized alkyl or alkenyl, etc.; W = amino, alkylamino, hydroxy, alkoxy, carbamoyl, amidino, cycloalkyl, heteroaryl, heterocyclyl, etc.] were prepared as modulators of melanocortin receptors, particularly MC-1R and MC-4R. Thus, peptide I was prepared by a solution-phase peptide coupling/deprotection scheme.

IT **457904-14-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides for pharmaceutical use as modulators of melanocortin receptors)

RN 457904-14-2 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-hydroxy-4-(2-phenoxyphenyl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:636061 CAPLUS <<LOGINID::20070205>>
DN 127:293135
TI Preparation of piperidinylalkylphenyldihydropyridinecarboxylate derivatives as neuropeptide Y antagonists.
IN Poindexter, Graham S.; Bruce, Marc; Johnson, Graham; Leboulluec, Karen; Sloan, Charles P.
PA Bristol-Myers Squibb Company, USA
SO U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 482,353, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5668151	A	19970916	US 1996-639968	19960508
	CA 2177110	A1	19961208	CA 1996-2177110	19960522
	AT 211733	T	20020115	AT 1996-109043	19960605
	PT 747357	T	20020628	PT 1996-109043	19960605
	ES 2169774	T3	20020716	ES 1996-109043	19960605
	AU 9654758	A	19961219	AU 1996-54758	19960606

Print selected from 10551870.trn

	AU 720923	B2	20000615		
	JP 09003045	A	19970107	JP 1996-145272	19960607
PRAI	US 1995-482353	B2	19950607		
OS	MARPAT 127:293135				
GI					



I

AB Title compds. (I; R1 = alkyl; R2, R3 = cyano, alkyl; R4 = CO2R1, 3-methyl-1,2,4-oxadiazol-5-yl; R5 = H, halo, OH, alkyl, alkoxy, alkenyloxy; B = NH, NR1, O, bond; n = 2-5; Z = 4-substituted-piperidin-1-yl, 4-substituted-1,2,3,6-tetrahydropiperidin-1-yl, etc.), were prepared for promoting weight loss and treating eating disorders (no data). Thus, di-Me 1,4-dihydro-4-[3-[[3-chloro-1-oxo-1-propyl]amino]phenyl]-1,6-dimethyl-3,5-pyridinedicarboxylate, 4-phenylpiperidine, and K2CO3 were refluxed 24 h in MeCN to give 100% di-Me 1,4-dihydro-4-[3-[[3-(4-phenylpiperidin-1-yl)-1-oxo-1-propyl]amino]phenyl]-2,6-dimethyl-3,5-piperidinedicarboxylate.

IT **186185-23-9P 186185-51-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinylalkylphenyldihydropyridinecarboxylate derivs. as neuropeptide Y antagonists)

RN 186185-23-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-hydroxy-4-(2-phenoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 186185-51-3 CAPLUS

Print selected from 10551870.trn

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-hydroxy-4-(2-phenoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester (9CI) (CA INDEX NAME)



IT **186185-96-6P 186185-97-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperidinylalkylphenyldihydropyridinecarboxylate derivs. as neuropeptide Y antagonists)

RN 186185-96-6 CAPLUS
CN 4-Piperidinol, 4-(2-phenoxyphenyl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 186185-97-7 CAPLUS
CN 4-Piperidinol, 4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:111046 CAPLUS <<LOGINID::20070205>>
DN 126:117870
TI Preparation of 4-(3-carboxamidophenyl)-1,4-dihydropyridine-3,5-dicarboxylates as neuropeptide Y antagonists
IN Poindexter, Graham S.; Bruce, Marc; Johnson, Graham; Leboulluec, Karen; Sloan, Charles P.
PA Bristol-Myers Squibb Company, USA
SO Eur. Pat. Appl., 38 pp.
CODEN: EPXXDW

Print selected from 10551870.trn

DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 747357	A2	19961211	EP 1996-109043	19960605
	EP 747357	A3	19981216		
	EP 747357	B1	20020109		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CA 2177110	A1	19961208	CA 1996-2177110	19960522
	AT 211733	T	20020115	AT 1996-109043	19960605
	PT 747357	T	20020628	PT 1996-109043	19960605
	ES 2169774	T3	20020716	ES 1996-109043	19960605
	AU 9654758	A	19961219	AU 1996-54758	19960606
	AU 720923	B2	20000615		
	JP 09003045	A	19970107	JP 1996-145272	19960607
PRAI	US 1995-482353	A	19950607		

OS MARPAT 126:117870
GI



AB Title compds. [I; R = C6H3R5R6-4,3; R1 alkyl; R2,R3 = cyano or alkyl; R4 = cyano, CO2R1, 3-methyl-1,2,4-oxadiazol-5-yl; R5 = H, halo, alkyl, alkoxy; R6 = NHCOZ(CH2)nR7; R7 = 4-arylpiperidino, 4-aryl-1,2,3,6-tetrahydropyridinyl, etc.; Z = bind, O, (alkyl)imino; n = 2-5] were prepared Thus, MeCOCH2CO2Bu was cyclocondensed with MeC(NH2):CHCO2Me and 3-(O2N)C6H4CHO to give I (R1 = R2 = R3 = Me)[II; R = C6H4(NO2)-3, R4 = CO2Bu]. II [R4 = CO2Me, R = C6H4(NO2)-3] was converted in 2 steps to title compound III (R7 = Cl) which was aminated by 4-phenylpiperidine to give III (R7 = 4-phenylpiperidino). Data for biol. activity of I were given.

IT **186185-23-9P 186185-51-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-(3-carboxamidophenyl)-1,4-dihydropyridine-3,5-dicarboxylates as neuropeptide Y antagonists)

RN 186185-23-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-hydroxy-4-(2-phenoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



● HCl

RN 186185-51-3 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-hydroxy-4-(2-phenoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester (9CI) (CA INDEX NAME)



IT **186185-96-6P 186185-97-7P**, 4-(2-Phenoxyphenyl)-4-piperidinol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-(3-carboxamidophenyl)-1,4-dihydropyridine-3,5-dicarboxylates as neuropeptide Y antagonists)

RN 186185-96-6 CAPLUS
CN 4-Piperidinol, 4-(2-phenoxyphenyl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 186185-97-7 CAPLUS
CN 4-Piperidinol, 4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1980:471576 CAPLUS <<LOGINID::20070205>>
DN 93:71576
TI Spiro[dibenz(b,f)oxepinepiperidines]
IN Ong, Helen H.; Profitt, James A.
PA American Hoechst Corp., USA
SO U.S., 20 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4198418	A	19800415	US 1979-2348	19790110
	EP 16261	A1	19801001	EP 1979-105373	19791227
	EP 16261	B1	19821229		
	R: AT, BE, CH, DE, FR, GB, IT, NL, SE				
	AT 2147	T	19830115	AT 1979-105373	19791227
	ES 487451	A1	19801201	ES 1980-487451	19800104
	AU 8054590	A	19800717	AU 1980-54590	19800109
	AU 522045	B2	19820513		
	ZA 8000115	A	19801231	ZA 1980-115	19800109
	CA 1142940	A1	19830315	CA 1980-343372	19800109
	AU 534512	B2	19840202	AU 1980-54490	19800109
	JP 55094387	A	19800717	JP 1980-2516	19800110
PRAI	US 1979-2348	A	19790110		
	EP 1979-105373	A	19791227		

OS MARPAT 93:71576
GI



I

AB Cyclocondensation of 4-(2-phenoxyphenyl)-4-piperidinecarboxylic acids gave spiro compds. I [R = H, alkyl, alkenyl, alkynyl, hydroxyalkyl, cycloalkylalkyl, (un)substituted phenylalkyl, phenoxyalkyl, or benzoylalkyl, cyano, A (p = 1-4; R2 defined below); Z = O, (H, OH) (OH, OAc); n, m (same or different) = 1, 2; R1, R2 (same or different) = H, Cl, F, Br, OMe, SMe, CF3], which exhibited analgesic, tranquilizer, and anticonvulsant activity. Thus, 1-acetyl-4-(2-phenoxyphenyl)-4-piperidinecarboxylic acid was converted to the acid chloride, which was

heated with AlCl3 in CH2Cl2 to give I (R = Ac, Z = O, n = m = 1, R1 = R2 = H).

IT **70764-61-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acyl chlorination of)
RN 70764-61-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-acetyl-4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



IT **70764-62-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cyclocondensatin reaction of, spiro compound from)
RN 70764-62-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-acetyl-4-[2-(4-fluorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



IT **70764-46-4P 70764-47-5P 74403-79-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation reaction of, spiro compound from)
RN 70764-46-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-[2-(4-fluorophenoxy)phenyl]-1-methyl- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



RN 70764-47-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-[2-(4-chlorophenoxy)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 74403-79-5 CAPLUS
CN 4-Piperidinecarbonyl chloride, 1-acetyl-4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



IT **70764-57-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and demethylation of, by cyanogen bromide)
RN 70764-57-7 CAPLUS
CN 4-Piperidinecarbonitrile, 1-methyl-4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



IT **70764-43-1P 70764-44-2P 70764-58-8P**
70764-59-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 70764-43-1 CAPLUS
CN 4-Piperidinecarbonitrile, 4-[2-(4-fluorophenoxy)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 70764-44-2 CAPLUS
CN 4-Piperidinecarbonitrile, 4-[2-(4-chlorophenoxy)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 70764-58-8 CAPLUS
CN 1,4-Piperidinedicarbonitrile, 4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



RN 70764-59-9 CAPLUS
CN 1,4-Piperidinedicarbonitrile, 4-[2-(4-fluorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



IT **70764-80-6P 74403-97-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and N-acetylation of)
RN 70764-80-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-(2-phenoxyphenyl)-, hydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 74403-97-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-[2-(4-fluorophenoxy)phenyl]- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



IT **70764-42-0P 70764-81-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 70764-42-0 CAPLUS
CN 4-Piperidinecarbonitrile, 1-methyl-4-(2-phenoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 70764-81-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-[2-(4-fluorophenoxy)phenyl]-, hydrobromide (9CI) (CA INDEX NAME)



● HBr

Print selected from 10551870.trn

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1980:471568 CAPLUS <<LOGINID::20070205>>
DN 93:71568
TI Phenoxyphenylpiperidines
IN Ong, Helen H.; Profitt, James A.
PA American Hoechst Corp., USA
SO U.S., 17 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4198417	A	19800415	US 1979-2346	19790110
	DE 2952213	A1	19800724	DE 1979-2952213	19791222
	JP 55094363	A	19800717	JP 1980-2515	19800110
	FR 2446283	A1	19800808	FR 1980-462	19800110
	FR 2446283	B1	19830708		
	GB 2043632	A	19801008	GB 1980-913	19800110
	GB 2043632	B	19830615		
PRAI	US 1979-2346	A	19790110		

OS MARPAT 93:71568
GI



I

AB 4-(Phenoxyphenyl)piperidines I [R and R1 (same or different) = H, Cl, F, Br, OMe, SMe, CF3; n and m (same or different) = 1, 2; R2 = cyano, CO2H, COCl, COF, COBr, alkanoyl, alkoxycarbonyl; R3 = H, alkyl, alkenyl, alkynyl, cycloalkylalkyl, phenylalkyl, alkanoyl, CO2PH, CONH2, benzoylalkyl, cyano, A (p = 1-4; m and R1 same as above), tetrahydrofurylmethyl], which were prepared by different methods, showed analgesic, antidepressant, and anticonvulsant activity. Thus, 2-PhOC6H4CH2CN was treated with (ClCH2CH2)2NMe.HCl in DMF containing NaH at 80-5° for 15 h to give I (n = m = 1, R = R1 = H, R2 = cyano, R3 = Me).

IT **74442-37-8P 74442-39-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn and pharmacol. activity of)

RN 74442-37-8 CAPLUS
CN 1-Propanone, 1-[1-(cyclopropylmethyl)-4-(2-phenoxyphenyl)-4-piperidinyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 74442-36-7
CMF C24 H29 N O2

Print selected from 10551870.trn



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 74442-39-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-(cyclopropylmethyl)-4-(2-phenoxyphenyl)-, ethyl ester, hydrobromide (9CI) (CA INDEX NAME)



● HBr

IT **74442-20-9P 74442-29-8P 74442-32-3P**
74453-36-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and analgesic activity of)
RN 74442-20-9 CAPLUS
CN 1-Propanone, 1-[1-methyl-4-(2-phenoxyphenyl)-4-piperidinyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 74442-19-6
CMF C21 H25 N O2

Print selected from 10551870.trn



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 74442-29-8 CAPLUS
CN 1-Propanone, 1-[4-(2-phenoxyphenyl)-1-(2-phenylethyl)-4-piperidinyl]-, hydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 74442-32-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-(2-phenoxyphenyl)-, ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 74442-31-2
CMF C20 H23 N O3

Print selected from 10551870.trn



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 74453-36-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-methyl-4-(2-phenoxyphenyl)-, ethyl ester, hydrobromide (9CI) (CA INDEX NAME)



● HBr

IT **74442-45-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and anticonvulsant activity of)
RN 74442-45-8 CAPLUS
CN Ethanone, 1-[1-(cyclopropylmethyl)-4-(2-phenoxyphenyl)-4-piperidinyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 74442-44-7
CMF C23 H27 N O2

Print selected from 10551870.trn



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **74442-50-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deprotection of)
RN 74442-50-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]propyl]-4-(2-phenoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT **70764-42-0P 74442-22-1P 74442-24-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and pharmacol. activity of)
RN 70764-42-0 CAPLUS
CN 4-Piperidinecarbonitrile, 1-methyl-4-(2-phenoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



● HCl

RN 74442-22-1 CAPLUS
CN Ethanone, 1-[1-methyl-4-(2-phenoxyphenyl)-4-piperidinyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 74442-21-0
CMF C20 H23 N O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 74442-24-3 CAPLUS
CN 1-Butanone, 1-[1-methyl-4-(2-phenoxyphenyl)-4-piperidinyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 74442-23-2

Print selected from 10551870.trn

CMF C22 H27 N O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **70764-43-1P 70764-44-2P 70764-46-4P**
70764-47-5P 70764-57-7P 70764-58-8P
70764-59-9P 70764-60-2P 70764-61-3P
70764-62-4P 70764-80-6P 70764-81-7P
74403-79-5P 74403-97-7P 74442-19-6P
74442-21-0P 74442-23-2P 74442-25-4P
74442-26-5P 74442-27-6P 74442-28-7P
74442-30-1P 74442-32-3P 74442-33-4P
74442-34-5P 74442-35-6P 74442-36-7P
74442-38-9P 74442-40-3P 74442-41-4P
74442-42-5P 74442-43-6P 74442-44-7P
74442-46-9P 74442-47-0P 74442-48-1P
74442-49-2P 74442-51-6P 74442-52-7P
74442-53-8P 74442-54-9P 74442-55-0P
74453-34-2P 74453-35-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 70764-43-1 CAPLUS
CN 4-Piperidinecarbonitrile, 4-[2-(4-fluorophenoxy)phenyl]-1-methyl- (9CI)
(CA INDEX NAME)



Print selected from 10551870.trn

RN 70764-44-2 CAPLUS
CN 4-Piperidinecarbonitrile, 4-[2-(4-chlorophenoxy)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 70764-46-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-[2-(4-fluorophenoxy)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 70764-47-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-[2-(4-chlorophenoxy)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 70764-57-7 CAPLUS
CN 4-Piperidinecarbonitrile, 1-methyl-4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



RN 70764-58-8 CAPLUS
CN 1,4-Piperidinedicarbonitrile, 4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 70764-59-9 CAPLUS
CN 1,4-Piperidinedicarbonitrile, 4-[2-(4-fluorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 70764-60-2 CAPLUS
CN 1,4-Piperidinedicarbonitrile, 4-[2-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



RN 70764-61-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-acetyl-4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 70764-62-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-acetyl-4-[2-(4-fluorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 70764-80-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-(2-phenoxyphenyl)-, hydrobromide (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



● HBr

RN 70764-81-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-[2-(4-fluorophenoxy)phenyl]-, hydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 74403-79-5 CAPLUS
CN 4-Piperidinecarbonyl chloride, 1-acetyl-4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 74403-97-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-[2-(4-fluorophenoxy)phenyl]- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



RN 74442-19-6 CAPLUS
CN 1-Propanone, 1-[1-methyl-4-(2-phenoxyphenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 74442-21-0 CAPLUS
CN Ethanone, 1-[1-methyl-4-(2-phenoxyphenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 74442-23-2 CAPLUS
CN 1-Butanone, 1-[1-methyl-4-(2-phenoxyphenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



RN 74442-25-4 CAPLUS
CN 1-Piperidinecarbonitrile, 4-acetyl-4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 74442-26-5 CAPLUS
CN Ethanone, 1-[4-(2-phenoxyphenyl)-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 74442-27-6 CAPLUS
CN 1-Piperidinecarbonitrile, 4-(1-oxopropyl)-4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



RN 74442-28-7 CAPLUS
CN 1-Propanone, 1-[4-(2-phenoxyphenyl)-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 74442-30-1 CAPLUS
CN 1-Propanone, 1-[4-(2-phenoxyphenyl)-1-(2-phenylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 74442-32-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-(2-phenoxyphenyl)-, ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 74442-31-2
CMF C20 H23 N O3

Print selected from 10551870.trn



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 74442-33-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-(2-phenoxyphenyl)-1-(2-phenylethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 74442-34-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-(2-phenoxyphenyl)-1-(2-phenylethyl)-, ethyl ester, hydrobromide (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



● HBr

RN 74442-35-6 CAPLUS
CN 1-Propanone, 1-[4-(2-phenoxyphenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 74442-36-7 CAPLUS
CN 1-Propanone, 1-[1-(cyclopropylmethyl)-4-(2-phenoxyphenyl)-4-piperidinyl]-
(9CI) (CA INDEX NAME)



RN 74442-38-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-(cyclopropylmethyl)-4-(2-phenoxyphenyl)-,
ethyl ester (9CI) (CA INDEX NAME)



Print selected from 10551870.trn

RN 74442-40-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-cyano-4-(2-phenoxyphenyl)-, phenyl ester (9CI) (CA INDEX NAME)



RN 74442-41-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-methyl-4-(2-phenoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 74442-42-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-(aminocarbonyl)-4-[2-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 74442-43-6 CAPLUS
CN Ethanone, 1-[4-(2-phenoxyphenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



RN 74442-44-7 CAPLUS
CN Ethanone, 1-[1-(cyclopropylmethyl)-4-(2-phenoxyphenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 74442-46-9 CAPLUS
CN 4-Piperidinecarbonitrile, 4-[2-(4-fluorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 74442-47-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-(2-phenoxyphenyl)-1-(2-propenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 74442-48-1 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-(2-phenoxyphenyl)-1-(2-propenyl)-, ethyl

Print selected from 10551870.trn

ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 74442-47-0
CMF C23 H27 N O3



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 74442-49-2 CAPLUS
CN 4-Piperidinecarbonitrile, 4-[2-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 74442-51-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[4-(4-fluorophenyl)-4-oxobutyl]-4-(2-phenoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



RN 74442-52-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[4-(4-fluorophenyl)-4-oxobutyl]-4-(2-phenoxyphenyl)-, ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 74442-51-6
CMF C30 H32 F N O4



CM 2

CRN 144-62-7
CMF C2 H2 O4

Print selected from 10551870.trn



RN 74442-53-8 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[4-(1-oxopropyl)-4-(2-phenoxyphenyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 74442-54-9 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[4-(1-oxopropyl)-4-(2-phenoxyphenyl)-1-piperidinyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 74442-53-8
CMF C30 H32 F N O3



Print selected from 10551870.trn

CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 74442-55-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 74453-34-2 CAPLUS
CN 1-Propanone, 1-[4-(2-phenoxyphenyl)-1-[(tetrahydro-2-furanyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 74453-35-3 CAPLUS
CN 1-Propanone, 1-[4-(2-phenoxyphenyl)-1-[(tetrahydro-2-furanyl)methyl]-4-piperidinyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 74453-34-2
CMF C25 H31 N O3

Print selected from 10551870.trn



CM 2

CRN 144-62-7
CMF C2 H2 O4



L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1980:76260 CAPLUS <<LOGINID::20070205>>
DN 92:76260
TI Studies on psychotropic agents. V. Synthesis of 1-substituted spiro[dibenz[b,f]oxepin-11,4'-piperidine]-10(11H)-one and related compounds
AU Nagai, Yasutaka; Uno, Hitoshi
CS Res. Lab., Dainippon Pharm. Co., Ltd., Suita, Japan
SO Chemical & Pharmaceutical Bulletin (1979), 27(9), 2056-64
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
OS CASREACT 92:76260
GI

Print selected from 10551870.trn



I



II



III



IV



V



VI

AB Spiro compds. (I; R = Me, PhCH2; Z = bond, O, CH2) were prepared by a sequence of reactions involving the pinacol rearrangement of 9-(1-ethoxycarbonyl-4-piperidinyl)fluorene-9,4'-diol or the cyclization of 1-benzyl-4-(o-substituted phenyl)-4-carboxy(or cyano)piperidine. Pyridylxanthene or -anthracene derivs. II and III and phenanthro[9,10-d]azepine derivative IV were also prepared by the Wagner-Meerwein rearrangement of α-hydroxy spiro compds. V. Among the compds. synthesized, the spiro(azepinefluorene) derivative VI showed marked anticonvulsant activity.

IT **72643-57-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)

RN 72643-57-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-(2-phenoxyphenyl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **72643-53-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 72643-53-9 CAPLUS

CN 4-Piperidinecarbonitrile, 4-(2-phenoxyphenyl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1979:468295 CAPLUS <<LOGINID::20070205>>
DN 91:68295
TI Synthesis and analgesic activity of some spiro[dibenz[b,f]oxepin-10,4'-piperidine] derivatives
AU Ong, Helen H.; Profitt, James A.; Spaulding, Theodore C.; Wilker, Jeffrey C.
CS Chem. Res. Dep., Hoechst-Roussel Pharm., Inc., Somerville, NJ, 08876, USA
SO Journal of Medicinal Chemistry (1979), 22(7), 834-9
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI



I

AB The title compds. I (X = H, Cl, or F; R = H, alkyl, cycloalkyl, or aralkyl) were prepared by several methods and tested for analgesic activity by the phenylquinone writhing and tail-flick assays in mice. I (X = F; R = H, HCl) [70764-82-8] given orally was most active, equipotent to morphine and 10 times more active than propoxyphene. In general, compds. with large N substituents (R>C2) showed low activity. Structure-activity relations are discussed.
IT **70764-57-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(demethylation of)
RN 70764-57-7 CAPLUS
CN 4-Piperidinecarbonitrile, 1-methyl-4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Print selected from 10551870.trn



IT **70764-80-6P 70764-81-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and N-acetylation of)
RN 70764-80-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-(2-phenoxyphenyl)-, hydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 70764-81-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-[2-(4-fluorophenoxy)phenyl]-, hydrobromide (9CI) (CA INDEX NAME)



● HBr

IT **70764-42-0P 70764-43-1P 70764-44-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acid hydrolysis of)

Print selected from 10551870.trn

RN 70764-42-0 CAPLUS
CN 4-Piperidinecarbonitrile, 1-methyl-4-(2-phenoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 70764-43-1 CAPLUS
CN 4-Piperidinecarbonitrile, 4-[2-(4-fluorophenoxy)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 70764-44-2 CAPLUS
CN 4-Piperidinecarbonitrile, 4-[2-(4-chlorophenoxy)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



IT **70764-61-3P 70764-62-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

Print selected from 10551870.trn

(preparation and cyclization of)
RN 70764-61-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-acetyl-4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 70764-62-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-acetyl-4-[2-(4-fluorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



IT **70764-45-3P 70764-46-4P 70764-47-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclodehydration of)
RN 70764-45-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-methyl-4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



Print selected from 10551870.trn

RN 70764-46-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-[2-(4-fluorophenoxy)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 70764-47-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-[2-(4-chlorophenoxy)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



IT **70764-58-8P 70764-59-9P 70764-60-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 70764-58-8 CAPLUS
CN 1,4-Piperidinedicarbonitrile, 4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 70764-59-9 CAPLUS
CN 1,4-Piperidinedicarbonitrile, 4-[2-(4-fluorophenoxy)phenyl]- (9CI) (CA

Print selected from 10551870.trn

INDEX NAME)



RN 70764-60-2 CAPLUS
CN 1,4-Piperidinedicarbonitrile, 4-[2-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1975:606112 CAPLUS <<LOGINID::20070205>>
DN 83:206112
TI Xanthene derivatives
IN Galt, Ronald H. B.; Pearce, Robert J.
PA Imperial Chemical Industries Ltd., UK
SO Ger. Offen., 88 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2504643	A1	19750807	DE 1975-2504643	19750204
	GB 1447583	A	19760825	GB 1974-5016	19740204
	SE 7501159	A	19750805	SE 1975-1159	19750103
	ZA 7500165	A	19760128	ZA 1975-165	19750109
	US 4001419	A	19770104	US 1975-539742	19750109
	AU 7577253	A	19760715	AU 1975-77253	19750113
	IN 140039	A1	19760904	IN 1975-CA78	19750113
	NL 7501090	A	19750806	NL 1975-1090	19750130
	BE 825129	A1	19750804	BE 1975-153012	19750203
	NO 7500341	A	19750805	NO 1975-341	19750203
	FR 2259606	A1	19750829	FR 1975-3263	19750203
	FR 2259606	B1	19800125		
	AT 7500773	A	19770415	AT 1975-773	19750203
	AT 340417	B	19771212		

Print selected from 10551870.trn

	FI 7500302	A	19750805	FI 1975-302	19750204
	JP 50112374	A	19750903	JP 1975-14763	19750204
	DK 7500376	A	19750929	DK 1975-376	19750204
	DD 118283	A5	19760220	DD 1975-183991	19750204
	ES 434431	A1	19770316	ES 1975-434431	19750204
	CS 188938	B2	19790330	CS 1975-718	19750204
	SU 581869	A3	19771125	SU 1975-2302642	19751225
	AT 7607536	A	19770515	AT 1976-7536	19761011
	AT 340917	B	19780110		
	AT 7607537	A	19770515	AT 1976-7537	19761011
	AT 340918	B	19780110		
	US 4268514	A	19810519	US 1976-732293	19761014
	DK 7703497	A	19770804	DK 1977-3497	19770804
	DK 7703498	A	19770804	DK 1977-3498	19770804
PRAI	GB 1974-5016	A	19740204		
	US 1975-539742	A1	19750109		
	AT 1975-773	A	19750203		
	DK 1975-376	A	19750204		

OS MARPAT 83:206112

GI For diagram(s), see printed CA Issue.

AB Analgesic (no data) spiropiperidinexanthenes I (R = H, alkyl, substituted alkyl, alkenyl; R1 = H, OH, SH, OMe, acyloxy, Cl, Me, CF3, CH2OH, NHAc; R2 = H, OMe, SOMe, SMe, Cl, CF3, F, OH, OAc) (128 compds) were prepared Thus xanthene was treated with MeSCH2Na and MeN(CH2CH2Cl)2 to give I (R = Me, R1 = R2 = H).

IT **57316-99-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)

RN 57316-99-1 CAPLUS

CN 4-Piperidinol, 1-methyl-4-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)